Commentary: Consensus statement on negative symptoms

Schizophrenia Bulletin

Volumn 32, Issue 2, 2006, Pages 223-224

  Kane, John ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; ZIPRASIDONE;

CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE COST; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL DISABILITY;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; COGNITION; CONSENSUS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33645219105     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbj010     Document Type: Conference Paper

References (2)

1. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
2. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893-896.